Press Releases
Date picker
Category
Results per page
Kancera’s ROR inhibitors show superior efficacy in 3D pancreatic tumor model.
Kancera today announced that its ROR inhibitor show effect in an advanced and challenging human pancreatic cancer model. In the model, the Kancera compounds show superior efficacy compared to gemcitabine,…
Full Year Report 2011 for Kancera AB (publ)
Regulatory
January 1 - December 31, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's…
Kancera’s ROR-inhibitor provides higher specificity than competing products
On February 8th Kancera's CEO, Dr. Thomas Olin, presented the company and new data in its ROR inhibitor project on the "6th Swiss-Scandinavian Bio-Business Seminar" in Zurich. In his presentation…
Kancera file patents for ROR inhibitors against cancer
Kancera reports that the company has registered a patent application (EP12153357) for new substances that prevents the ability of the cancer to survive. The new patent is based on Kancera's…
Kanceras strategy is given attention when global expertise in cancer gathers in Washington DC
Today Kanceras Chief Scientific Officer, Professor Lars Ährlund-Richter, presents the company and its PFKFB3 inhibitor project at the World Cancer Metabolism Summit in Washington. The meeting brings together world experts…
iNovacia announces collaboration with Agios Pharmaceuticals
iNovacia AB, the provider of small molecule drug discovery services, today announced that it has entered into a high-throughput screening collaboration with Agios Pharmaceuticals, Cambridge (MA), USA.
Kancera strengthens its patent portfolio in cancer metabolism
Kancera report that the Company has registered a patent application for novel compounds targeting the energy metabolism of cancer. The new patent application covers a strategy to facilitate the uptake…
iNovacia, GE Healthcare and scientists at Karolinska Institutet collaborate to advance drug discovery strategies
In an ongoing and open collaboration between iNovacia AB, GE Healthcare, Sweden and scientists at the Department of Medical Biochemistry and Biophysics (MBB) at Karolinska Institutet, the surface plasmon resonance…
Further clinical support for ROR1 as a diagnostic tool and therapeutic target
Kancera co-founder and scientific adviser Professor Håkan Mellstedt has demonstrated a sustained presence of Kancera's ROR1 target over time in patients with non-progressive disease and also a significant increase of…
Interim Report for Kancera AB (publ)
Regulatory
January 1 - September 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's…